Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Current Signal: SELL (auto-tracking)
0.37% $75.38
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 17 694 mill |
EPS: | 2.11 |
P/E: | 35.73 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 234.73 mill |
Avg Daily Volume: | 1.788 mill |
RATING 2024-04-19 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 2/23 | 3/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 35.73 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.08x |
Company: PE 35.73 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
$97.98 (29.98%) $22.60 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 74.12 - 76.64 ( +/- 1.68%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-14 | Garrett Scott T | Buy | 7 402 | Common Stock |
2024-03-14 | Garrett Scott T | Buy | 9 039 | Common Stock |
2024-03-14 | Garrett Scott T | Sell | 16 441 | Common Stock |
2024-03-14 | Garrett Scott T | Sell | 7 402 | Non-qualified Stock Option (Right to Buy) |
2024-03-14 | Garrett Scott T | Sell | 9 039 | Non-qualified Stock Option (Right to Buy) |
INSIDER POWER |
---|
12.42 |
Last 100 transactions |
Buy: 489 871 | Sell: 374 668 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $75.38 (0.37% ) |
Volume | 1.195 mill |
Avg. Vol. | 1.788 mill |
% of Avg. Vol | 66.82 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $73.13 | N/A | Active |
---|
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.